1
|
Scola L, Bongiorno MR, Forte GI, Aiello A, Accardi G, Scrimali C, Spina R, Lio D, Candore G. TGF-β/VEGF-A Genetic Variants Interplay in Genetic Susceptibility to Non-Melanocytic Skin Cancer. Genes (Basel) 2022; 13:genes13071235. [PMID: 35886018 PMCID: PMC9317818 DOI: 10.3390/genes13071235] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2022] [Revised: 07/10/2022] [Accepted: 07/11/2022] [Indexed: 12/04/2022] Open
Abstract
Differential genetically determined expression of transforming growth factor-β (TGF-β pathway and of vascular endothelial growth factor-A (VEGF-A) might modulate the molecular “milieu” involved in the etio-pathogenesis of non-melanoma skin cancer (NMSC). We have evaluated the frequency of some functionally relevant SNPs of TGF-β and VEGF-A genes in 70 NMSC patients and 161 healthy controls, typed for TGF-β1 rs1800471, TGF-β2 rs900, TGF-βR1 rs334348 and rs334349, TGF-βR2 rs4522809 and VEGF-A rs3025039 SNPs. TGF-βR2 rs1800629G allele and related genotypes were found to be associated with a possible protective role against NMSC, whereas VEGF-A rs3025039T was associated with an increased risk. To evaluate the effect of genotype combinations on NMSC susceptibility, we determined the frequencies of 31 pseudo-haplotypes due to non-random linkage among alleles of loci not lying on the same chromosome. Two pseudo-haplotypes that imply a minor allele of TGF-βR2 or minor allele of VEGF-A SNPs combined with major alleles of the other SNPs were, respectively, associated with a protective effect, and susceptibility to NMSC. In addition, a pseudo-haplotype involving minor alleles of TGF-β2 rs900, TGF-βR1 rs334348 and rs4522809 SNPs might be a susceptibility marker for NMSC. In conclusion, our data suggest that a complex interplay among the genetic polymorphisms of TGF-β, TGF-β receptors and VEGF-A genes might influence the net effect of genetic background of the patients on NMSC development. This might be relevant in the risk evaluation, diagnosis and treatment of NMSC.
Collapse
Affiliation(s)
- Letizia Scola
- Clinical Pathology, Department of Bio-Medicine, Neuroscience, and Advanced Diagnostics, University of Palermo, 90135 Palermo, Italy;
| | - Maria Rita Bongiorno
- Section of Dermatology, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo, 90127 Palermo, Italy;
| | - Giusi Irma Forte
- Institute of Bioimaging and Molecular Physiology, National Research Council (IBFM-CNR), 90015 Cefalù, Italy;
| | - Anna Aiello
- General Pathology, Department of Bio-Medicine, Neuroscience, and Advanced Diagnostics, University of Palermo, 90135 Palermo, Italy; (A.A.); (G.A.); (G.C.)
| | - Giulia Accardi
- General Pathology, Department of Bio-Medicine, Neuroscience, and Advanced Diagnostics, University of Palermo, 90135 Palermo, Italy; (A.A.); (G.A.); (G.C.)
| | - Chiara Scrimali
- Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo, 90127 Palermo, Italy; (C.S.); (R.S.)
| | - Rossella Spina
- Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo, 90127 Palermo, Italy; (C.S.); (R.S.)
| | - Domenico Lio
- Interdepartmental Research Center “Migrate”, University of Palermo, 90135 Palermo, Italy
- Correspondence:
| | - Giuseppina Candore
- General Pathology, Department of Bio-Medicine, Neuroscience, and Advanced Diagnostics, University of Palermo, 90135 Palermo, Italy; (A.A.); (G.A.); (G.C.)
| |
Collapse
|
2
|
Fathi F, Zamani B, Piroozmand A, Mozafarpoor S, Seyedhashemi E, ArefNezhad R, Motedayyen H. Programmed cell death 1 (PDCD1) gene haplotypes and susceptibility of patients to basal cell carcinoma. Mol Biol Rep 2021; 48:2047-2052. [PMID: 33389528 DOI: 10.1007/s11033-020-06115-w] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2020] [Accepted: 12/20/2020] [Indexed: 02/08/2023]
Abstract
Programmed death-1 (PD-1), as an immunoinhibitory receptor encoded by programmed cell death-1 (PDCD1) gene, has a pivotal role in tolerance to self-antigens. Mutations of PDCD1 may participate in susceptibility to basal cell carcinoma (BCC) as the most common of skin cancer. We studied the impacts of two single nucleotide polymorphisms (SNPs) within PDCD1 and their haplotypes in BCC susceptibility in an Iranian population. The blood samples were collected from 210 BCC and 220 healthy individuals. After the extraction of genomic DNA, the genotypes and alleles of PD1.1 G/A (rs36084323) and PD1.6 G/A (rs10204525) SNPs were determined by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). Four haplotypes were estimated by these SNPs. Our data revealed that genotype and allele frequencies of PD1.1 and PD1.6 polymorphisms in BCC patients were similar to those in healthy individuals. The results of estimated haplotypes for PDCD1 indicated that GG and AA haplotypes of PDCD1 had protective effects on BCC susceptibility (OR = 0.7, 95% CI = 0.51-0.96, p = 0.03 and OR = 0.57, 95% CI = 0.35-0.91, p = 0.02, respectively), while GA and AG haplotypes served as the risk factors for developing BCC (OR = 1.76, 95% CI = 1.09-2.84, p = 0.02 and OR = 3.87, 95% CI = 1.95-7.69, p = <0.001, respectively). Based on these findings, frequency distributions of PDCD1 haplotypes have important roles in the determination of BCC development in the Iranian population. However, larger multicenter studies are required to confirm this conclusion.
Collapse
Affiliation(s)
- Farshid Fathi
- Department of Immunology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
| | - Batool Zamani
- Autoimmune Diseases Research Center, Kashan University of Medical Sciences, Kashan, Iran
| | - Ahmad Piroozmand
- Autoimmune Diseases Research Center, Kashan University of Medical Sciences, Kashan, Iran.,Department of Microbiology, Faculty of Medicine, Kashan University of Medical Sciences, Kashan, Iran
| | - Samaneh Mozafarpoor
- Department of Dermatology, Isfahan University of Medical Sciences, Isfahan, Iran
| | - Effat Seyedhashemi
- Department of Genetics, Faculty of Advanced Science and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran
| | - Reza ArefNezhad
- Department of Anatomy, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
| | - Hossein Motedayyen
- Autoimmune Diseases Research Center, Shahid Beheshti Hospital, Kashan University of Medical Sciences, 5th kilometer of Ravand Road, Kashan, Iran.
| |
Collapse
|
3
|
Bissonnette R, Maari C, Forman S, Bhatia N, Lee M, Fowler J, Tyring S, Pariser D, Sofen H, Dhawan S, Zook M, Zammit D, Usansky H, Denis L, Rao N, Song T, Pavel A, Guttman‐Yassky E. The oral Janus kinase/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate-to-severe atopic dermatitis: results from a randomized double-blind placebo-controlled study. Br J Dermatol 2019; 181:733-742. [PMID: 30919407 PMCID: PMC6850605 DOI: 10.1111/bjd.17932] [Citation(s) in RCA: 84] [Impact Index Per Article: 16.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/24/2019] [Indexed: 12/30/2022]
Abstract
BACKGROUND ASN002 is an oral dual inhibitor of Janus kinase and spleen tyrosine kinase, which are involved in the pathogenesis of atopic dermatitis (AD) through their regulatory role on T helper (Th)1, Th2 and Th17/Th22 pathways. OBJECTIVES The objectives of this study were to evaluate the efficacy, safety, pharmacokinetics and effects on systemic biomarkers of ASN002 in patients with moderate-to-severe AD. Methods A total of 36 patients with moderate-to-severe AD were randomized (3 : 1) to ASN002 or placebo in the phase Ib study. Three dosage cohorts were studied over a 28-day period (20 mg, 40 mg and 80 mg once daily). RESULTS ASN002 was superior to placebo for the proportion of patients achieving Eczema Area and Severity Index (EASI) 50 (20 mg 20%, P = 0·93; 40 mg 100%, P = 0·003; 80 mg 83%, P = 0·03; placebo 22%), EASI 75 (20 mg 0%, P = 0·27; 40 mg 71%, P = 0·06; 80 mg 33%, P = 0·65; placebo 22%) and in change from baseline in pruritus (20 mg -1·3 ± 2·1, P = 0·81; 40 mg -3·1 ± 2·7, P = 0·27; 80 mg -4·7 ± 2·1, P = 0·01; placebo -1·6 ± 1·8). Adverse events were generally mild and similar across all groups. ASN002 showed dose-dependent plasma exposure with low interpatient variability, significantly downregulated several serum biomarkers involved in Th1, Th2 and Th17/Th22 immunity, and decreased the atherosclerosis-associated biomarker E selectin/SELE. CONCLUSIONS In patients with moderate-to-severe AD, ASN002 showed strong efficacy with rapid onset of action and associated improvements in systemic inflammation.
Collapse
Affiliation(s)
- R. Bissonnette
- Innovaderm Research Inc.1851 Sherbrooke Street East, Suite 502MontrealH2K 4L5QuebecCanada
| | - C. Maari
- Innovaderm Research Inc.1851 Sherbrooke Street East, Suite 502MontrealH2K 4L5QuebecCanada
| | - S. Forman
- Forward Clinical Trials, Inc.4915 Ehrlich RoadTampa33624FLU.S.A
| | - N. Bhatia
- Therapeutics Clinical Research9025 Balboa Avenue, Suite 105San Diego92123CAU.S.A
| | - M. Lee
- Progressive Clinical ResearchP.A., LLC1973 North West Loop 410, Suite 106San Antonio78213TXU.S.A
| | - J. Fowler
- Dermatology Specialists Research3810 Springhurst Boulevard, Suite 130Louisville40241KYU.S.A
| | - S. Tyring
- Center for Clinical StudiesUniversity of Texas Health Science Center451 North Texas AvenueHouston77598TXU.S.A
| | - D. Pariser
- Department of DermatologyEastern Virginia Medical School and Virginia Clinical Research Inc.6160 Kempsville Circle, Suite 200ANorfolk23502VAU.S.A
| | - H. Sofen
- Dermatology Research Associates8930 South Sepulveda BoulevardLos Angeles90045CAU.S.A
| | - S. Dhawan
- Center for Dermatology Clinical Research Inc.2557 Mowry Avenue, Suite 21 and 25Fremont94538CAU.S.A
| | - M. Zook
- Olympian Clinical Research1201 South Myrtle AvenueClearwater33756FLU.S.A
| | - D.J. Zammit
- Asana BioSciences, LLC997 Lenox Drive, Suite 220, Princeton Pike Corporate CenterLawrenceville08648NJU.S.A
| | - H. Usansky
- Asana BioSciences, LLC997 Lenox Drive, Suite 220, Princeton Pike Corporate CenterLawrenceville08648NJU.S.A
| | - L. Denis
- Asana BioSciences, LLC997 Lenox Drive, Suite 220, Princeton Pike Corporate CenterLawrenceville08648NJU.S.A
| | - N. Rao
- Asana BioSciences, LLC997 Lenox Drive, Suite 220, Princeton Pike Corporate CenterLawrenceville08648NJU.S.A
| | - T. Song
- Icahn School of Medicine at Mount Sinai1425 Madison Avenue, Icahn Building 13‐76New York10029NYU.S.A
| | - A.B. Pavel
- Icahn School of Medicine at Mount Sinai1425 Madison Avenue, Icahn Building 13‐76New York10029NYU.S.A
| | - E. Guttman‐Yassky
- Icahn School of Medicine at Mount Sinai1425 Madison Avenue, Icahn Building 13‐76New York10029NYU.S.A
| |
Collapse
|
4
|
Fathi F, Ebrahimi M, Eslami A, Hafezi H, Eskandari N, Motedayyen H. Association of programmed death-1 gene polymorphisms with the risk of basal cell carcinoma. Int J Immunogenet 2019; 46:444-450. [PMID: 31293069 DOI: 10.1111/iji.12447] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2019] [Revised: 05/31/2019] [Accepted: 06/05/2019] [Indexed: 02/06/2023]
Abstract
Environmental and genetic factors play a fundamental role in the pathogenesis of basal cell carcinoma (BCC) defined as the most common cancer of skin. Programmed death-1 (PD-1), encoded by programmed cell death-1 (PDCD1) gene, serves as an inhibitory molecule in the suppression of immune responses and a risk factor in the development of different cancers. In this study, we investigated the role of two single nucleotide polymorphisms (SNPs) within PDCD1 gene, and haplotypes defined by these SNPs, in the development of BCC in an Iranian population. Whole blood samples were obtained from 210 BCC and 320 healthy subjects. Genomic DNA was extracted from whole blood samples, polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) was used to genotype determinations of PD1.3 (rs11568821) and PD1.5 (rs2227981) SNPs, and 4 haplotypes were constructed by PDCD1 SNPs. The frequency of G allele of PD1.3 was significantly higher in BCC patients than healthy subjects (p < 0.02), while these significant differences were not observed in the frequencies of PD1.5 alleles between BCC and healthy subjects. Moreover, we found that there were no statistically significant differences in PD1.3 and PD1.5 genotypes between BCC and control groups. Of all estimated haplotypes for PDCD1, only AC haplotype was associated with BCC (OR = 0.22, 95% CI = 0.06-0.79, p < 0.01). These findings suggest that PD1.3G allele and AC haplotype of PDCD1 contribute to BCC in the Iranian population. However, further studies in different populations with larger sample size are required to confirm this study.
Collapse
Affiliation(s)
- Farshid Fathi
- Department of Immunology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
| | - Milad Ebrahimi
- Faculty of Medicine, Department of Immunology, Shahed University, Tehran, Iran
| | - Asma Eslami
- Department of Immunology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
| | - Hossein Hafezi
- Department of Dermatology, Isfahan University of Medical Sciences, Isfahan, Iran
| | - Nahid Eskandari
- Department of Immunology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
| | - Hossein Motedayyen
- Autoimmune Diseases Research Center, Kashan University of Medical Sciences, Kashan, Iran
| |
Collapse
|
5
|
Wu TW, Chou CL, Chen YC, Juang YL, Wang LY. Associations of Common Genetic Variants on IL-17 Genes and Carotid Intima-Media Thickness. J Atheroscler Thromb 2018; 25:1156-1167. [PMID: 29695654 PMCID: PMC6224208 DOI: 10.5551/jat.44453] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
AIM Atherosclerosis is a chronic inflammatory process of the arterial wall and carotid intima-media thickness (cIMT) is regarded as its early marker. Several members of the IL-17 family are involved in pro-inflammatory functions. The specific aim of the study was to explore the relationships of common genetic variants on IL-17 genes with cIMT thickening. METHODS In the discovery stage, 146 SNPs on 11 IL-17 genes were screened for their relationships with cIMT by a case-control study that enrolled 284 and 464 subjects who had thicker and normal cIMT, respectively. Findings were replicated by an independent case-control study that enrolled 282 subjects who had thicker cIMT and 282 age-sex-matched subjects who had normal cIMT. RESULTS Among 134 eligible SNPs in the discovery study, only IL-17RC rs279545 was significantly correlated with cIMT (p=6.9×10-5). The rs279545 and 2 nearby linked SNPs rs55847610 and rs3846167 were included in the validation study. We found that the rs279545*G, rs55847610*G, and rs3846167*C were correlated with significantly higher likelihoods of having thicker cIMT. The corresponding multivariate-adjusted ORs were 1.462 (95% CI: 1.055-2.027), 1.481 (95% CI:1.090-2.013), and 1.589 (95% CI: 1.147-2.200), respectively. Analyses of rs279545-rs55847610 haplotypes showed that the multivariate-adjusted OR for A-A haplotype was significantly decreased (OR=0.665, 95% CI: 0.487-0.908) and for G-G haplotype was significantly increased (OR=1.539, 95% CI: 1.097-2.161). CONCLUSIONS We first correlated cIMT, a preclinical clinical cardiovascular marker, with IL-17RC, the key molecule in the IL-17 signaling pathway. Our results indicated that IL-17RC may play critical role in the development of atherosclerotic diseases.
Collapse
Affiliation(s)
- Tzu-Wei Wu
- Department of Medicine, Mackay Medical College
| | - Chao-Liang Chou
- Department of Medicine, Mackay Medical College.,Department of Neurology, Mackay Memorial Hospital
| | | | - Yue-Li Juang
- Institute of Biomedical Sciences, Mackay Medical College
| | - Li-Yu Wang
- Department of Medicine, Mackay Medical College.,Institute of Biomedical Sciences, Mackay Medical College
| |
Collapse
|
6
|
Du B, Wu D, Yang X, Wang T, Shi X, Lv Y, Zhou Z, Liu Q, Zhang W. The expression and significance of microRNA in different stages of colorectal cancer. Medicine (Baltimore) 2018; 97:e9635. [PMID: 29384843 PMCID: PMC5805415 DOI: 10.1097/md.0000000000009635] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/26/2022] Open
Abstract
BACKGROUND The aim of this study is to compare microRNA expression patterns in different stages of colorectal cancer (CRC) and to discuss the significance of the application of microRNAs in the clinical treatment of CRC. METHODS The study used gene chip technology to analyze genetic sequences in CRC tissues and surrounding normal tissues at different cancer stages. The bioinformatics profiles of the target genes of the different microRNAs were analyzed to clarify the target gene-related pathways and their functions in the disease. RESULTS A total of 368 target genes with differential expression, including 275 upregulated and 93 downregulated genes, were screened from CRC patients in different stages of the disease. These microRNAs participated widely in the occurrence and development processes of CRC. The microRNA expression profiles obviously differed in tissues at different CRC stages. CONCLUSION microRNA regulation of CRC samples can be used as a tool to control the occurrence and development of tumor cells.
Collapse
Affiliation(s)
- Binbin Du
- Department of Colorectal Surgery, Gansu Provincial Hospital, Lanzhou
| | - Dewang Wu
- Department of Colorectal Surgery, Gansu Provincial Hospital, Lanzhou
- Department of Surgery, Ningxia Medical University, Yinchuan
| | - Xiongfei Yang
- Department of Colorectal Surgery, Gansu Provincial Hospital, Lanzhou
| | - Tao Wang
- Department of Colorectal Surgery, Gansu Provincial Hospital, Lanzhou
| | - Xinlong Shi
- Department of Colorectal Surgery, Gansu Provincial Hospital, Lanzhou
| | - Yaochun Lv
- Department of Colorectal Surgery, Gansu Provincial Hospital, Lanzhou
- Department of Surgery, Ningxia Medical University, Yinchuan
| | - Zhuolong Zhou
- School of Medical Instrument and Food Engineering, University of Shanghai for Science and Technology, Shanghai, China
| | - Qing Liu
- School of Medical Instrument and Food Engineering, University of Shanghai for Science and Technology, Shanghai, China
| | - Weisheng Zhang
- Department of Colorectal Surgery, Gansu Provincial Hospital, Lanzhou
| |
Collapse
|